{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:15:46Z","timestamp":1781774146740,"version":"3.54.5"},"reference-count":25,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Female survivors of Hodgkin lymphoma (HL) treated with chest radiotherapy have a strongly increased risk of breast cancer (BC), but the treatment-specific BC risk in male survivors of HL has not been evaluated. We assessed BC risk in a cohort of 3077 male survivors of 5-year HL treated at age \u226451 years in 20 Dutch hospitals between 1965 and 2013. We estimated standardized incidence ratios (SIRs), absolute excess risks per 10\u2009000 person-years, and cumulative BC incidences. After a 20-year median follow-up, we observed 8 cases of male with BC. Male survivors of HL experienced a 23-fold (95% confidence interval [CI], 10.1-46.0) increased BC risk compared with the general population, representing 1.6 (95% CI, 0.7-3.3) excess BC incidences per 10\u2009000 person-years. The 20- and 40-year cumulative BC incidences after HL treatment were 0.1% (95% CI, 0.02-0.3) and 0.7% (95% CI, 0.3-1.4), respectively. Treatment with chest radiotherapy without alkylating chemotherapy yielded a strongly increased SIR (20.7; 95% CI, 2.5-74.8), which was not significantly different for chest radiotherapy and alkylating chemotherapy (41.1; 95% CI, 13.4-96.0). Males treated with chest radiotherapy and anthracyclines had an SIR of 48.1 (95% CI, 13.1-123.1). Two patients died from BC (median follow-up, 4.7 years). To ensure early diagnosis and treatment, clinicians should be alert to BC symptoms in male survivors of HL.<\/jats:p>","DOI":"10.1182\/blood.2023020940","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T18:13:58Z","timestamp":1688148838000},"page":"806-811","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Risk of male breast cancer after Hodgkin lymphoma"],"prefix":"10.1182","volume":"142","author":[{"given":"Simone","family":"de Vries","sequence":"first","affiliation":[{"name":"1Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"Krul","sequence":"additional","affiliation":[{"name":"1Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schaapveld","sequence":"additional","affiliation":[{"name":"1Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3860-8698","authenticated-orcid":false,"given":"Cecile P. M.","family":"Janus","sequence":"additional","affiliation":[{"name":"2Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia E.","family":"Rademakers","sequence":"additional","affiliation":[{"name":"3Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith M.","family":"Roesink","sequence":"additional","affiliation":[{"name":"4Department of Radiotherapy, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9069-4939","authenticated-orcid":false,"given":"Marten R.","family":"Nijziel","sequence":"additional","affiliation":[{"name":"5Department of Hemato-Oncology, Catharina Cancer Institute, Eindhoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavuz M.","family":"Bilgin","sequence":"additional","affiliation":[{"name":"6Department of Internal Medicine, Adrz, Goes, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthe M. P.","family":"Aleman","sequence":"additional","affiliation":[{"name":"7Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora E.","family":"van Leeuwen","sequence":"additional","affiliation":[{"name":"1Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"22","key":"2023083115243286800_bib1","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2011.38.8835","article-title":"Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study","volume":"30","author":"Swerdlow","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2023083115243286800_bib2","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2006.09.0936","article-title":"Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma","volume":"25","author":"Hodgson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023083115243286800_bib3","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-02-0634","article-title":"Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors","volume":"100","author":"Ng","year":"2002","journal-title":"Blood"},{"issue":"26","key":"2023083115243286800_bib4","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023083115243286800_bib5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ijrobp.2017.07.016","article-title":"Breast cancer risk after radiation therapy for Hodgkin lymphoma: influence of gonadal hormone exposure","volume":"99","author":"Krul","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"2023083115243286800_bib6","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/jamapediatrics.2019.3807","article-title":"Association of breast cancer risk after childhood cancer with radiation dose to the breast and anthracycline use: a report from the childhood cancer survivor study","volume":"173","author":"Veiga","year":"2019","journal-title":"JAMA Pediatr"},{"issue":"9","key":"2023083115243286800_bib7","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/jnci\/djac125","article-title":"Radiotherapy-related dose and irradiated volume effects on breast cancer\u00a0risk among Hodgkin lymphoma survivors","volume":"114","author":"Roberti","year":"2022","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"26","key":"2023083115243286800_bib8","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1200\/JCO.2008.19.9174","article-title":"Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes","volume":"27","author":"de Bruin","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023083115243286800_bib9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jama.290.4.465","article-title":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease","volume":"290","author":"Travis","year":"2003","journal-title":"JAMA"},{"issue":"11","key":"2023083115243286800_bib10","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1038\/bjc.2013.219","article-title":"Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors","volume":"108","author":"Cooke","year":"2013","journal-title":"Br J Cancer"},{"issue":"8","key":"2023083115243286800_bib11","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/cncr.31807","article-title":"Risk of solid subsequent malignant neoplasms after childhood Hodgkin lymphoma-identification of high-risk populations to guide surveillance: a report from the Late Effects Study Group","volume":"125","author":"Holmqvist","year":"2019","journal-title":"Cancer"},{"key":"2023083115243286800_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2022.01.001","article-title":"Male breast cancer after childhood cancer: Systematic review and analyses in the PanCareSurFup cohort","volume":"165","author":"Wang","year":"2022","journal-title":"Eur J Cancer"},{"issue":"3","key":"2023083115243286800_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2013-10-532184","article-title":"Risk of multiple primary malignancies following treatment of Hodgkin lymphoma","volume":"124","author":"van Eggermond","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2023083115243286800_bib14","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2023083115243286800_bib15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2000.18.3.487","article-title":"Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood","volume":"18","author":"van Leeuwen","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"2023083115243286800_bib16","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin's disease","volume":"21","author":"Aleman","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2023083115243286800_bib17","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2008-10-184705","article-title":"Malignant mesothelioma after radiation treatment for Hodgkin lymphoma","volume":"113","author":"De Bruin","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2023083115243286800_bib18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/ije\/22.3.369","article-title":"Completeness of cancer registration in Limburg, The Netherlands","volume":"22","author":"Schouten","year":"1993","journal-title":"Int J Epidemiol"},{"issue":"3","key":"2023083115243286800_bib19","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/ijc.32750","article-title":"Ascertainment of cancer in longitudinal research: the concordance between the Rotterdam Study and the Netherlands Cancer\u00a0Registry","volume":"147","author":"van der Willik","year":"2020","journal-title":"Int J Cancer"},{"issue":"82","key":"2023083115243286800_bib20","first-page":"1","article-title":"Statistical methods in cancer research. Volume II--the design and analysis of cohort studies","author":"Breslow","year":"1987","journal-title":"IARC Sci Publ"},{"key":"2023083115243286800_bib21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1742-5573-7-4","article-title":"Fitting additive Poisson models","volume":"7","author":"Boshuizen","year":"2010","journal-title":"Epidemiol Perspect Innov"},{"issue":"9","key":"2023083115243286800_bib22","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.2015.62.3314","article-title":"Breast cancer risk in childhood cancer survivors without a history of chest radiotherapy: a report from the childhood cancer survivor study","volume":"34","author":"Henderson","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"2023083115243286800_bib23","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2016.71.6902","article-title":"Long-term risk of subsequent malignant neoplasms after\u00a0treatment of childhood cancer in the DCOG LATER Study Cohort: role of chemotherapy","volume":"35","author":"Teepen","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"34","key":"2023083115243286800_bib24","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1200\/JCO.19.00129","article-title":"Chemotherapy and risk of subsequent malignant neoplasms in the Childhood Cancer Survivor Study cohort","volume":"37","author":"Turcotte","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"2023083115243286800_bib25","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1200\/JCO.18.01099","article-title":"Subsequent breast cancer in female childhood cancer survivors in the St Jude Lifetime Cohort Study (SJLIFE)","volume":"37","author":"Ehrhardt","year":"2019","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/9\/806\/2075217\/blood_bld-2023-020940-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/9\/806\/2075217\/blood_bld-2023-020940-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T15:50:09Z","timestamp":1693497009000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/9\/806\/496681\/Risk-of-male-breast-cancer-after-Hodgkin-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,8,31]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023020940","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]}}}